This article is within the scope of WikiProject Companies, a collaborative effort to improve the coverage of companies on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.CompaniesWikipedia:WikiProject CompaniesTemplate:WikiProject Companiescompany articles
This article is within the scope of WikiProject Denmark, a collaborative effort to improve the coverage of Denmark on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.DenmarkWikipedia:WikiProject DenmarkTemplate:WikiProject DenmarkDenmark articles
This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
There are no sources stated in this article, please could someone cite some! --w2ch00
Also, the timeline section is apparently copied from the corporate site. I don't know about copyvio, but most of that stuff is of little importance, so it should be stripped to the essentials. Anyone? I might do it some day. Muad 04:37, 24 January 2007 (UTC)[reply]
I was reading this and getting warm-fuzzy feelings about this company, which I expressed to my gf, she asked me why, so I read aloud, eg. "including the most advanced products within the area of insulin delivery systems"... And I instantly realized this is patently FALSE. The most advanced insulin delivery systems are electronic pumps, made by companies like Medtronic-Minimed, Disetronic, Cosmo. Novo-Nordisk does NOT make any pumps. In fact, they've recently regressed into Flexpens which are inferior to Penfills, in which they formerly specialized.
So this information is partisan spin, and FALSE, and the article needs to be updated to balance this. Kirez 16:19, 23 March 2007 (UTC)[reply]
I don't agree with Kirez's stance on the article, it is my belief that pulmonary delivery systems are the future of diabetes delivery instruments, to which point I understand Novo Nordisk has strong development in.dojon 09:59, 3 July 2007 (UTC)[reply]
I think that Novo Nordisk are focussing upon pulmonary delivery as they have judged it to be a future market. But in the UK and the USA, at least, insulin pumps are the money-no-object treatment method of choice.
I will try to NPOV this, mentioning pulmonary delivery and pumps. Wee Jimmy (talk) 19:47, 30 June 2008 (UTC)[reply]
This portion of the article makes it sound as if Novo is responsible for the creation of World Diabetes Day when in actuality they are one sponsor out of many and the corporation had little to do with it. A List of the corporate sponsors can be found here: http://www.worlddiabetesday.org/en/the-campaign/world-diabetes-day-partners I am new to wikipedia and unsure how to fix this. InfiniteThinking (talk) 22:37, 9 July 2009 (UTC)[reply]
I don't particularly agree. The reference provided seems fine, and it does not claim any responsibility for 'creating' World Diabetes Day. In fact, it labels the campaign as that of the International Diabetes Federation, so I can not see what you are trying to sat. Taymaishu (talk) 05:18, 24 August 2009 (UTC)[reply]
Upon re-read, Taymaishu is correct. I think that I am having bias problems as I know someone who was involved in International Diabetes Federation, and I will not work on this article any more. Thank you for your input. InfiniteThinking (talk) 00:14, 27 August 2009 (UTC)[reply]
I have deleted a paragraph in the Translational Immunology section. The reason for doing this is that some statements in this paragraph are not yet scientifically validated and peer reviewed and we have not been able to confirm the existence of the lecture that is referred to as source. Additionally some of the statements could also be regarded as promotional content. Kasper Kofod 14:44, 5 March 2012 (UTC) — Preceding unsigned comment added by Kofod (talk • contribs)
I'm Social Media Manager at Novo Nordisk A/S. We would like to update and correct a few things in the article on Novo Nordisk. There is also a few things I hope you can help me clarify:
We haven't edited the article, except for one factual error, to avoid having it labeled as advertisement, but still it is labeled as advertisement. Is there anything we can do to remove this label?
The other label says that the article needs additional citations for verification. Is it possible to see exactly where citations are needed?
We would like to update and correct a few things in the article:
Update the general information at the top of the article with the following: Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 36,000 employees in 75 countries, and markets its products in more than 180 countries[1].
Update the current text in the section about Toxicogenomics with the following: Novo Nordisk is involved in collaborative research projects with other industrial and academic partners. The company is for example active in joint research projects within the framework of the Innovative Medicines Initiative among others IMIDIA[2], DIRECT[3] and EUPATI[4].
Merge the section about Translational immunology into the section about Inflammation and correct the outdated information. The two sections would then be one section called Inflammation with the following text: Novo Nordisk is developing immunotherapies to combat chronic inflammatory diseases including rheumatoid arthritis, lupus, inflammatory bowel disease, and psoriatic arthritis. At research facilities in USA[5], China[6] and Denmark, Novo Nordisk is using its expertise in designing therapeutic proteins and chronic disease management care to develop new treatments in this area.
Update and correct the timeline with the following:
1923 Nordisk Insulinlaboratorium (later Nordisk Gentofte) founded by Hans Christian Hagedorn, August Krogh and August Kongsted.
1925 Novo Terapeutisk Laboratorium (later Novo Industri) founded by the former Nordisk employees, the brothers Thorvald Pedersen and Harald Pedersen.
1946 Nordisk develops isophane insulin, branded as Neutral Protamine Hagedorn or NPH insulin, a neutral insulin with prolonged action.
1977 Novo introduces Trisequens – sequential combined oral hormone replacement therapy (HRT) for peri-menopausal women – is marketed.
1984 Novo Industri A/S enters a joint venture with Canada's Connaught Laboratories, considered to be the birthplace of insulin.
1992 The Steno Memorial Hospital and Hvidøre Hospital merge to form the Steno Diabetes Center in Gentofte, Denmark.
2007 In Montes Claros, Brazil, Novo Nordisk inaugurates the company’s largest production facility outside of Denmark.
I would like to make the above changes to the article. Can anyone tell me how long it would be appropriate to wait for comments to my suggestions on the talk page before I make the changes to the article?
Kasper Kofod 09:23, 7 November 2013 (UTC)
Hello Kasper, and welcome to Wikipedia. I have checked your articles and tried to correct some of the issues with it, so we can remove those labels from the top of the the page. To that effect, I have also removed some of the text matter inside the article as they were not required for the article itself.
Before I explain about the rest of the things, there are two in particular I need to point out to you -
A longer article isn't always better. In general, short but precise articles are much more preffered by editors, and will have a lot lesser issues and tags
Every article must have secondaryreliable sources. Sources that are backed only by the company itself, or organisations associated with it are called Primary sources, and are considered weak. Paragraphs using them can be removed, and usually are, which is why we use secondary sources for making the article and supporting it.
Now about the Timeline section, I removed it because it needed to be converted into prose. We do not want articles to remain as a list, but as readable text. We also do not want it to be too long and cluttered with information. Hence the article ought to be removing some of the timeline, and instead have only the more significant parts of the timeline in it.
You are permitted to make minor changes and factual corrections to your article, so long as your edits are non controversial. If an editor disagrees with you, then discussion on this page follows, where the decision will be made depending on consensus and Wikipedia policies. Keeping the article in best shape according to wikipedia policy trumps everything else. Please see WP:COI for more information
Finally, I have already mentioned what kind of citations you can include to make your article better, and get that citations tag removed. We are searching for Neutral Secondary reliable sources. As long as such sources are there in adequacy, we can remove the tag.
Hope this helped,
Please feel free to contact me again for further information and help.
We will draft a timeline/history section in prose and add neutral secondary reliable sources where possible.
And thanks for permission to make minor changes and factual corrections to the article, so long as the edits are not controversial.
Regards,: Kofod (talk) 21:31, 23 January 2014 (UTC)[reply]
Hi, I work at Novo Nordisk and have noticed that the 'fact box' could be updated - specifically the key people (executive management and board of directors), products and financials (which you can find in the latest Annual Report). Hope this helps, thank you Det1015 (talk) 11:23, 29 September 2016 (UTC)[reply]
The following section should be cleaned up, and converted into prose before being re-added into the article. All unnecessary and possibly trivial details must be removed. TheOriginalSoni (talk) 17:19, 7 November 2013 (UTC)[reply]
Novo Nordisk was created in 1989 through a merger between two Danish companies – Novo Industri A/S and Nordisk Gentofte A/S.
1925 Novo Terapeutisk Laboratorium (later Novo Industri) founded.
1932 Nordisk Insulinlaboratorium founds the Steno Memorial Hospital.
1938 Novo founds Hvidøre Diabetes Sanatorium.
1941 Novo launches its first enzyme, trypsin, extracted from the pancreas of animals and used for bating leather before tanning.
1946 Nordisk develops isophane insulin, branded as Neutral Protamine Haegdorn or NPH insulin, a neutral insulin with prolonged action.
1947 Penicillin Novo is launched – Novo's first product to be manufactured through fermentation.
1953 Lente – a long-acting insulin zinc suspension – is launched.
1963 Alcalase – Novo's first detergent enzyme produced by fermentation.
1973 Nordisk Gentofte markets Nanormon growth hormone for the treatment of growth hormone insufficiency. The growth hormone is extracted from human pituitary glands.
1973 Monocomponent (MC) insulin is introduced – the purest insulin available at the time.
1974 Novo's B shares are quoted on the Copenhagen Stock Exchange.
1977 Trisequens – sequential combined oral hormone replacement therapy (HRT) for peri-menopausal women – is marketed.
1977 Novo enters the U.S. insulin market, but based on market share data, the company was a very marginal player.
1978 In an effort to alleviate its product and quality problems in the U.S. insulin market, E.R. Squibb & Sons contracts with Novo. Novo becomes the single bulk supplier of insulin for Squibb.
1981 Novo becomes the first company in Scandinavia to be quoted on the New York Stock Exchange.
1982 Novo enters into a 50/50 U.S. joint venture with E.R. Squibb & Sons, known as Squibb-Novo, based in Princeton, NJ. Squibb-Novo became the distributor for Novo insulin sold in the U.S. market, with Novo focused on producing insulin, and Squibb focused on distributing and selling the product. The joint venture is able to significantly increase Novo's U.S. market share.
1982 'Human' Monocomponent insulin is launched in the U.S. – the world's first insulin preparation which is structurally identical to human insulin. It is extracted from the pancreas of pigs and converted to human insulin chemically.
1983 Novo Industri A/S enters a joint venture with Canada's Connaught Laboratories, considered to be the birthplace of insulin. Under the terms of the agreement, Novo agreed to manufacture insulin in Canada for distribution by Connaught. Novo Laboratories Ltd. agreed to lease, modernize and operate Connaught's insulin production facilities. Another subsidiary company, Connaught-Novo, was jointly owned by both parent companies. Connought Laboratories was privatized by the Mulroney government in 1985.
1985 NovoPen – an injection system similar in appearance to a fountain pen, with replaceable insulin cartridges – is launched.
1987 Novo starts production of biosynthetic human insulin with the help of genetically engineered yeast cells using recombinant DNA technology.
1988 Nordisk Gentofte markets Norditropin genetically engineered human growth hormone.
1989 Novo Industri A/S and Nordisk Gentofte A/S merge to become Novo Nordisk A/S, the world's leading producer of insulin.
1989 Following the merger of Novo and Nordisk, and the merger of Bristol-Myers and E.R. Squibb & Sons in the U.S., the Squibb-Novo joint venture in the U.S. market was dissolved. Novo purchased Squibb's 50% share and all rights to the joint U.S. diabetes care business.
1989 NovoLet – the world's first prefilled insulin syringe – is marketed.
1992 The Steno Memorial Hospital and Hvidøre Hospital merge to form the Steno Diabetes Center.
1994 Novo Nordisk Canada Inc. and Connaught Laboratories Ltd. announced a distribution agreement, which replaced their joint venture which was known as Connaught Novo Nordisk Inc. Under the terms of the agreement, Connaught received a financial consideration and a percentage fee for distribution services related to Novo Nordisk Canada's diabetes care products. Connaught continued to distribute Novo Nordisk Canada's diabetes products in Canada and Bermuda.
1996 NovoSeven – for the treatment of haemophilia patients with inhibitor reaction – is launched.
1998 NovoNorm/Prandin, a new oral treatment for type 2 diabetes, is launched in the US and a number of European countries.
1998 Activelle – the first low-dose continuous combined oral HRT for post-menopausal women – is introduced.
1999 Novo Nordisk publishes its first social report.
1999 Innovo, the world's first insulin doser with a built-in electronic memory, is launched in Europe.
1999 Novorapid (Novolog in the U.S.) – a rapid-acting insulin analogue – is marketed.
1999 Norditropin SimpleXx – the world’s first liquid growth hormone in a dedicated pen system – is launched.
2000 Novofem, a low-dose sequential combined oral HRT, is marketed in Germany. Two years later it is launched in several other European countries.
2000 Novo Nordisk is split into three separate companies operating under the umbrella of the Novo Group: Novo Nordisk A/S, Novozymes A/S and Novo A/S.
2001 InnoLet – the first insulin delivery system specially designed to suit the needs of insulin users with poor eyesight and reduced dexterity – is launched.
2001 InDuo – the world's first combined blood glucose monitor and insulin injection system – is introduced.
2001 NovoRapid/Novolog FlexPen and Insulatard (NPH) FlexPen are marketed. FlexPen is a new disposable, prefilled insulin pen dosage device.
2001 Novo Nordisk acquires the controlling interest in the Brazilian pharmaceutical company Biobrás, the dominant insulin manufacturer in Brazil.
2002 NovoMix 30 FlexPen and NovoMix Penfill are introduced. NovoMix 30 is a dual-release insulin analogue.
2004 Levemir – a long-acting insulin analogue – is launched.
2005 Novo Nordisk announced that the company had moved into a leadership position in the U.S. insulin market for the first time ever based on the most recent data on total insulin volume.[2]
2009 Novo Nordisk was named as an ethical leader of international business by think-tank Ethisphere.[4]
2009 Novo Nordisk agrees to pay a $9 Million fine in connection with the payment of $1.4 million in kickbacks through the United Nations Oil-for-food Program.[5]
2010 Novo Nordisk pulls medicine from Greece due to price cuts triggered by the financial crisis in the country. The act caused uproar among diabetics and relatives.[7]
2010 Novo Nordisk agreed to pay $25 million to the US government for illegally promoting its haemostasis management drug, NovoSeven.[8]
2011 The Association of the British Pharmaceutical Industry reprimands Novo Nordisk for poor management due to breaching industry codes concerning various promotional efforts for its Victoza diabetes medicine.[9]
Behind Novo Nordisk lies a story about two Danish firms - Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium. Nordisk Insulinlaboratorium was founded by Hans Christian Hagedorn, August Krogh and August Kongsted in 1923 in Copenhagen.
In 1922, August Krogh and his wife Marie Krogh travelled to the US. The couple had heard reports of people with diabetes being treated with insulin – a hormone discovered in 1921 by two Canadians, Frederick Banting and Charles Best. Marie Krogh was a doctor herself and also had type 2 diabetes. The couple returned to Denmark with permission to manufacture and sell insulin in Scandinavia. With the economic help from August Kongsted – the owner of Leo Pharmaceutical Products - Insulin Leo was marketed in 1923.
When Krogh and Hagedorn started manufacturing insulin, they hired Thorvald Petersen and his brother Harald Pedersen to build the machines for insulin production. However, Thovald Pedersen was fired from Nordisk and the two brothers decided to try to manu-facture insulin themselves. Thorvald and Harald Pedersen managed to produce a stable liquid insulin and marketed Insulin Novo in 1925.. The brothers named their firm Novo Terapeutisk Laboratorium. Over the next decades the products were further improved, e.g. with focus on longer effect; nevertheless, there were still challenges to be met, and in the 1970s the new goal was to produce human insulin meaning that Novo would no longer depend on animal pancreases. In 1982, Novo succeeded and launched the world’s first insulin preparation identical to human insulin.
Nordisk marketed a genetically engineered human growth hormone in 1988 and Novo Nordisk is market leading in the world today in this area and introduced the world’s first liquid growth hormone in a pen system in 1999.
In 1989, Novo Industri A/S (Novo Terapeutisk Laboratorium) and Nordisk Gentofte A/S (Nordisk Insulinlaboratorium) merged to become Novo Nordisk A/S, the world's largest producer of insulin with headquarters in Bagsværd, Copenhagen. In 2000 the company demerged into NovoZymes A/S and Novo Nordisk A/S.
Research into bleeding disorders lead to the foundation of The Novo Nordisk Haemophilia Foundation in 2005 striving to improve access to care for people with haemophilia and allied bleeding disorders.
Kofod (talk) Kasper Kofod 14:09, 25 February 2015 (UTC)[reply]
I removed this paragraph, which can be readded using reliable sources. TheOriginalSoni (talk) 17:39, 7 November 2013 (UTC)[reply]
The company has also inaugurated the Novo Nordisk Changing Diabetes World Tour — a truck that folds out into an educational and awareness-developing bus. The vehicle was launched in Copenhagen in September 2005 and has visited Europe, Africa, Australia, Asia, the Indian subcontinent and the United States. The bus journey culminated in being stationed in New York City for the inaugural World Diabetes Day on November 14, 2007.Cite error: A<ref> tag is missing the closing </ref> (see the help page). In March 2015, NNIT was floated on the NASDAQ OMX Nordic.
In 2000, the enzymes business was separated and thus born Novozymes A/S, a spin out from Novo Nordisk A/S.
In 2015, the company announced it would collaborate with Ablynx, using its nanobody technology to develop at least one new drug candidate.[10]
Jesper Brandgaard is the Executive Vice President and CFO of the global healthcare company Novo Nordisk A/S. Brandgaard has been the Vice Chairman of the board of directors in the Danish company SimCorp[11] since 2007.[12]
In January 2018, Reuters reported that Novo had offered to acquire Ablynx for $3.1 billion - having made an unreported offer in mid December for the company.[13] However the Ablynx board rejected this offer the same day, saying that the price undervalued the business.[14]
Products==
Ozempic® (semaglutide) is a once-weekly analogue of human glucagon-like peptide-1 (GLP-1) that has been developed for the treatment of type 2 diabetes. The review of Ozempic® is based on the SUSTAIN programme, a global clinical development programme that comprises eight phase 3a trials, encompassing more than 8,000 adults with type 2 diabetes. The phase 3a programme involves a broad range of people with type 2 diabetes, including some with high cardiovascular risk profiles and people with and without renal disease.
Ozempic® is currently under review by several regulatory agencies, including the European Medicines Agency and the Japanese Pharmaceuticals and Medical Devices Agency.
Tresiba – a Diabetes mellitus type 1 and Type 2 diabetes drug. It is a new-generation basal insulin with ultra-long duration of action of more than 42 hours administered through subcutaneous injection. Intended to offer a flexible treatment and a good safety profile. It is approved and launched in the EU and Japan and under regulatory review in the US and other major markets.[15]
Saxenda – a once-daily human GLP-1 analogue. It serves as an agonist, intended for combination with lifestyle changes (including diet), to offer sustainable weight loss for people with severe obesity, including those at particular risk of developing diabetes.[15]
Ryzodeg – a drug for type 1 and 2 diabetes. Ryzodeg is a soluble co-formulation of Tresiba and NovoRapid, and is a rapid-acting mealtime insulin. It is approved to offer patients reduced risk of hypoglycemia and is currently approved in the EU and Japan. US FDA also approved Ryzodeg & Tresiba on 25 September 2015 after reviewing the interim safety data of the ongoing CV outcome trial DEVOTE .[15]
Levemir – long-acting human insulin analogue for maintaining the basal level of insulin. It is an insulin analogue in which a fatty acid (myristic acid) is bound to the lysine amino acid at position B29. It is quickly absorbed after which it binds to albumin in the blood through its fatty acid at position B29. It then slowly dissociates from this complex.
NovoLog – a fast-acting insulin analog. It is a manufactured form of human insulin; where a single amino acid has been exchanged. This change helps the fast-acting insulin analog be absorbed quickly into the bloodstream. As a result, it starts working in minutes, which allows one to take insulin and eat right away. Fast-acting insulin analogs are considered to act similarly to the way insulin is released in people without diabetes mellitus.
NovoLog Mix 70/30 – is a product which contains 30% insulin aspart and 70% insulin aspart protamine. The insulin aspart protamine portion is a crystalline form of insulin aspart, which delays the action of the insulin, giving it a prolonged absorption profile after injection. The combination of the fast-acting form and the long-acting form allows the patient to receive fewer injections over the course of the day.
In addition to the development of diabetes treatment pharmaceuticals, Novo Nordisk has been involved in the production of several lines of insulin pumps/pens for efficient delivery into the body and bloodstream.
NovoEight – is a recombinant antihemophilic factor VIII used for the treatment of and prophylaxis of bleeding patients with haemophilia A.
1993 Novo A/S acquires Xellia Pharmaceuticals[edit]
Novo A/S and Novo Nordisk are two separate companies. Novo A/S is today named Novo Holdings and is responsible for the investments of the Novo Nordisk Foundation. Novo Nordisk is not owner of Xellia Pharmaceutical.
A Commons file used on this page or its Wikidata item has been nominated for speedy deletion[edit]
The following Wikimedia Commons file used on this page or its Wikidata item has been nominated for speedy deletion:
You can see the reason for deletion at the file description page linked above. —Community Tech bot (talk) 07:37, 11 March 2022 (UTC)[reply]
Guardian: Revealed: experts who praised new ‘skinny jab’ received payments from drug maker[edit]
There are several news outlets covering payments made by Novo Nordisk to experts and groups in relation to its new drug. I don't write medical articles so I'll let others chose how to add it to the article.
This article badly needs updating to reflect the impact of Ozempic and Wegovy on Novo Nordisk's recent success. At the moment, Ozempic is mentioned only once (on the sidebar) and Wegovy zero times. Given that these drugs are powering the company (and the Danish economy), this suggests that this article is in need of substantial revisions.
